Royal Bank of Canada’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $208K | Sell |
2,338
-912
| -28% | -$66.6K | ﹤0.01% | 4963 |
|
|
2026
Q1 | $164K | Buy |
3,250
+1,262
| +63% | +$47.6K | ﹤0.01% | 4829 |
|
|
2025
Q4 | $65K | Sell |
1,988
-5,895
| -75% | -$154K | ﹤0.01% | 5416 |
|
|
2025
Q3 | $132K | Sell |
7,883
-591
| -7% | -$9.64K | ﹤0.01% | 5344 |
|
|
2025
Q2 | $126K | Buy |
8,474
+6,302
| +290% | +$93.2K | ﹤0.01% | 5488 |
|
|
2025
Q1 | $35K | Sell |
2,172
-1,850
| -46% | -$38.5K | ﹤0.01% | 5707 |
|
|
2024
Q4 | $94K | Buy |
4,022
+236
| +6% | +$6.92K | ﹤0.01% | 5374 |
|
|
2024
Q3 | $111K | Buy |
3,786
+530
| +16% | +$14.8K | ﹤0.01% | 5272 |
|
|
2024
Q2 | $77K | Buy |
3,256
+3,200
| +5,714% | +$108K | ﹤0.01% | 5430 |
|
|
2024
Q1 | $2K | Buy |
+56
| New | +$1.62K | ﹤0.01% | 6704 |
|
|
2023
Q4 | – | Sell |
-437
| Closed | -$5K | – | 7567 |
|
|
2023
Q3 | $5K | Buy |
437
+384
| +725% | +$5.08K | ﹤0.01% | 6622 |
|
|
2023
Q2 | $1K | Buy |
+53
| New | +$251 | ﹤0.01% | 7080 |
|
|
2022
Q4 | – | Sell |
-56
| Closed | -$1K | – | 7700 |
|
|
2022
Q3 | $1K | Buy |
56
+29
| +107% | +$358 | ﹤0.01% | 7270 |
|
|
2022
Q2 | $0 | Sell |
27
-72
| -73% | -$2.52K | ﹤0.01% | 7700 |
|
|
2022
Q1 | $6K | Sell |
99
-227
| -70% | -$19.1K | ﹤0.01% | 7197 |
|
|
2021
Q4 | $39K | Buy |
326
+107
| +49% | +$16.9K | ﹤0.01% | 6512 |
|
|
2021
Q3 | $44K | Buy |
219
+100
| +84% | +$17.5K | ﹤0.01% | 6237 |
|
|
2021
Q2 | $20K | Sell |
119
-39
| -25% | -$7.09K | ﹤0.01% | 6567 |
|
|
2021
Q1 | $32K | Buy |
158
+83
| +111% | +$15.9K | ﹤0.01% | 6168 |
|
|
2020
Q4 | $15K | Buy |
75
+67
| +838% | +$13.9K | ﹤0.01% | 6204 |
|
|
2020
Q3 | $1K | Sell |
8
-2
| -20% | -$370 | ﹤0.01% | 6479 |
|
|
2020
Q2 | $2K | Sell |
10
-3
| -23% | -$571 | ﹤0.01% | 6309 |
|
|
2020
Q1 | $2K | Sell |
13
-78
| -86% | -$13.3K | ﹤0.01% | 6333 |
|
|
2019
Q4 | $18K | Buy |
91
+83
| +1,038% | +$16.3K | ﹤0.01% | 5910 |
|
|
2019
Q3 | $2K | Sell |
8
-6
| -43% | -$1.17K | ﹤0.01% | 6310 |
|
|
2019
Q2 | $2K | Buy |
14
+6
| +75% | +$1.04K | ﹤0.01% | 6602 |
|
|
2019
Q1 | $2K | Hold |
8
| – | – | ﹤0.01% | 6541 |
|
|
2018
Q4 | $1K | Sell |
8
-207
| -96% | -$43.9K | ﹤0.01% | 6611 |
|
|
2018
Q3 | $52K | Sell |
215
-254
| -54% | -$59.3K | ﹤0.01% | 5220 |
|
|
2018
Q2 | $124K | Buy |
469
+461
| +5,763% | +$113K | ﹤0.01% | 4693 |
|
|
2018
Q1 | $2K | Buy |
+8
| New | +$1.45K | ﹤0.01% | 6126 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6871 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6967 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Royal Bank of Canada's SYRE Position: Q2 2026 in Review
Royal Bank of Canada reduced its Spyre Therapeutics (SYRE) stake by 28% in Q2 2026, selling an estimated $66.6K and leaving 2,338 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #4963.
Royal Bank of Canada first reported a position in SYRE in Q1 2018 and has held it in 31 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Royal Bank of Canada held 2,338 shares of Spyre Therapeutics worth $208K as of Q2 2026.
- Royal Bank of Canada sold 912 Spyre Therapeutics shares in Q2 2026, an estimated $66.6K.
- Spyre Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4963 holding.
- Royal Bank of Canada first reported a position in Spyre Therapeutics in Q1 2018 and has held it in 31 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.